Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16447448 | 1.00 | ACHE (0.38) | ACHETDP1MAPTMAOACA7 | |
| SCHEMBL7886834 | 0.80 | CA12 (0.40) | ACHETDP1MAPTMAOACA7 | |
| SCHEMBL16414441 | 0.79 | IDO1 (0.38) | IDO1 | |
| SCHEMBL31589 | 0.78 | CYP3A4 (0.39) | TDP1MAOACYP2A6TAAR1 | |
| SCHEMBL28532 | 0.78 | CYP3A4 (0.39) | TDP1MAOACYP2A6TAAR1 | |
| SCHEMBL30277 | 0.78 | CYP3A4 (0.39) | TDP1MAOACYP2A6TAAR1 | |
| SCHEMBL1225131 | 0.78 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL10324073 | 0.78 | CYP3A4 (0.39) | TDP1MAOACYP2A6TAAR1 | |
| SCHEMBL6543955 | 0.78 | CYP3A4 (0.39) | TDP1MAOACYP2A6TAAR1 | |
| SCHEMBL25201319 | 0.77 | ACHE (0.44) | ACHETDP1MAPTMAOACA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2865446-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL | KANTO KAGAKU (JP) | 2021-09-22 | — | — | EP | claimed |
| US-9174906-B2 | Process for producing optically active secondary alcohol | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2015-11-03 | — | — | US | claimed |
| EP-2865446-A1 | Process for producing optically active secondary alcohol | Kanto Kagaku Kabushiki Kaisha (JP) | 2015-04-29 | — | — | EP | claimed |
| US-20150031920-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2015-01-29 | — | — | US | claimed |
| EP-1867654-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE QUINUCLIDINOL | NAGOYA IND SCIENCE RES INST (JP) | 2014-06-11 | — | — | EP | claimed |
| EP-2623509-A1 | Method of producing an optically active amine compound by catalytic asymmetric hydrogenation using a ruthenium-diphosphine complex | Kanto Kagaku Kabushiki Kaisha (JP) | 2013-08-07 | — | — | EP | claimed |
| US-20130197234-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE COMPOUND | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2013-08-01 | — | — | US | claimed |
| EP-1323724-B1 | Ruthenium complexes and process for preparing alcoholic compounds using these | KANTO KAGAKU (JP) | 2007-03-14 | — | — | EP | claimed |
| US-6790973-B2 | REDUCTION OF KETONE TO ALCOHOL USING COMPLEX CATALYST | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2004-09-14 | — | — | US | claimed |
| US-20030166978-A1 | Novel ruthenium complexes and process for preparing alcoholic compounds using these | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2003-09-04 | — | — | US | claimed |
| EP-1323724-A2 | Novel ruthenium complexes and process for preparing alcoholic compounds using these | Kanto Kagaku Kabushiki Kaisha (JP) | 2003-07-02 | — | — | EP | claimed |
| EP-2865446-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL | KANTO KAGAKU (JP) | 2021-09-22 | — | — | EP | disclosed |
| US-9174906-B2 | Process for producing optically active secondary alcohol | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2015-11-03 | — | — | US | disclosed |
| EP-2865446-A1 | Process for producing optically active secondary alcohol | Kanto Kagaku Kabushiki Kaisha (JP) | 2015-04-29 | — | — | EP | disclosed |
| US-20150031920-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2015-01-29 | — | — | US | disclosed |
| EP-1867654-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE QUINUCLIDINOL | Nagoya Industrial Science Research Institute (JP) | 2007-12-19 | — | — | EP | disclosed |
| EP-1323724-B1 | Ruthenium complexes and process for preparing alcoholic compounds using these | KANTO KAGAKU (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-6790973-B2 | REDUCTION OF KETONE TO ALCOHOL USING COMPLEX CATALYST | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20030166978-A1 | Novel ruthenium complexes and process for preparing alcoholic compounds using these | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1323724-A2 | Novel ruthenium complexes and process for preparing alcoholic compounds using these | Kanto Kagaku Kabushiki Kaisha (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031920-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL | ADH1A, ADH1C, ADH5 | ACHE 1428/4885TDP1 4079/4885MAPT 4522/4885 |
| US-20130197234-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE COMPOUND | HRH3, TDO2, SRM | ACHE 359/4885TDP1 3532/4885MAPT 4062/4885 |
| US-20030166978-A1 | Novel ruthenium complexes and process for preparing alcoholic compounds using these | ADH1C, ADH1A, ADH5 | ACHE 2291/4885TDP1 2662/4885MAPT 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.